The Utility of Estrogen Receptor and Progesterone Receptor Immunohistochemistry in the Distinction of Metastatic Breast Carcinoma From Other Tumors in the Liver

Abstract Context.—The distinction of metastatic breast adenocarcinoma (MBA) to the liver from hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and metastatic adenocarcinoma from other sites may require the use of immunohistochemistry. The use of antibodies directed against estrogen receptor (ER) and progesterone receptor (PR) has been suggested to help make this distinction. Objective.—To examine the utility of ER and PR immunohistochemistry in the distinction of MBA from HCC, CC, and other metastatic adenocarcinomas in the liver. Methods.—Ninety-two previously characterized hepatic neoplasms were identified, including HCC (n = 14), CC (n = 16), and metastatic tumors from breast (n = 17), colorectal (n = 14), pancreatic (n = 15), and esophageal/gastric (n = 16) origins. For all cases of metastatic tumor, the primary tumor was reviewed to verify the diagnosis. All tumors were graded as well, moderately, or poorly differentiated. Estrogen receptor and PR immunohistochemical staining was performed on all cases and evaluated by 2 pathologists. Results.—Immunoreactivity for ER was identified only in MBA, with 6 (35%) of 17 cases positive. Positive immunoreactivity for PR was not restricted to MBA, but was seen in HCC, CC, esophageal/gastric, and pancreatic metastases. Positive immunostaining with PR was nearly as frequent in poorly differentiated carcinomas of nonbreast origin (3/16 cases, 19%) as in poorly differentiated breast carcinomas (2/8 cases, 25%). Conclusion.—Progesterone receptor exhibited poor specificity and sensitivity for the distinction of MBA from HCC, CC, and other metastatic adenocarcinomas. Estrogen receptor exhibited poor sensitivity for MBA, although the specificity was good. The finding that PR positivity was present with a similar frequency in poorly differentiated tumors of breast and nonbreast origin limits the usefulness of this marker. Therefore, ER and PR staining have limited utility in the distinction of MBA from HCC, CC, and other metastatic adenocarcinomas in the liver.

Download Full-text

MMP9 EXPRESSION IN THE CYTOPLASM OF SURROUNDING STROMAL CELLS OF BREAST CARCINOMA IN RELATION TO PATHOLOGICAL STAGE, GRADE AND RECEPTOR STATUS

10.36106/ijsr/9202712 ◽

2021 ◽

pp. 1-3

Author(s):

Priyanka Saha ◽

Sandipan Banik ◽

Anadi Roy Chowdhury ◽

Tushar Kanti Das ◽

Debarshi Jana

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Breast Carcinoma ◽

Progesterone Receptor ◽

Early Stage ◽

Metastatic Breast ◽

The United States ◽

Receptor Expression ◽

Cross Sectional ◽

Her 2

INTRODUCTION Breast cancer is the most common malignancy and the second leading cause of cancer-related death after lung cancer among women in the United States and Europe. Due to major advances in screening and early diagnostic procedures, most breast cancer patients are diagnosed at an early stage. However, 6% to 10% of patients still present with metastatic breast cancer at the time of diagnosis; for those patients, relapses tend to occur earlier and survival rates are shortened. AIMS AND OBJECTIVES To study MMP 9, Estrogen receptor, Progesterone receptor and Her-2-Neu expression in breast carcinoma by immune histochemistry. Compare MMP 9 expression with result of Estrogen receptor expression, Progesterone receptor expression and Her-2-Neu expression in breast carcinoma. To study MMP 9 expression in relation to staging and grading of breast cancer. MATERIALS AND METHOD This cross-sectional study was conducted on a group of patients admitted in Department of General Surgery, R G Kar Medical College & Hospital, Kolkata from January 2018 - Jun 2019. Approval from an institutional review board was obtained at the initiation of the study. All patients were provided with signed informed written consent. Cross sectional, descriptive and observational. RESULTS AND PUBLICATION From the above table it is evident that only 2 of the patients with stage II tumor showed MMP9 positivity while 8 were negative, but in case of patients with stage III disease 20 out of 22 showed MMP9 positivity with only 2 of them showing a negative MMP9 pattern. From the above table it is evident that only 1 out of 6 cases with grade 1 breast cancer was positive for MMP9 , while 11 out of 16 cases of grade 2 disease showed MMP9 positivity and all cases with grade 3 was found to be MMP9 positive. The above table clearly shows that out of 12 ER positive breast cancer cases only one third i.e. 4 were MMP9 positive. However, out of 20 ER negative cases 90% i.e. 18 were found to be MMP9 positive.

Download Full-text